Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors.
Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...
Alnylam's nucresiran showed promising results in Phase 1 trial for rare cardiomyopathy, achieving up to 96% TTR reduction at ...
Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic ...
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...
The FDA on Monday offered new draft guidance to help drugmakers understand the nuts and bolts of FDA processes for developing and submitting an application for a new cell or gene therapy, from pre-IND ...
Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...
Atlas Venture, one of biotech’s go-to VC firms, is eyeing a $450 million 14th fund, partner Bruce Booth said in its ...
San Diego biotech Avenzo Therapeutics has in-licensed another asset, this time securing the global ex-China ...
Cybin said its psilocin analog has the potential to wipe out symptoms in most patients with a serious form of ...
In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery built around a class of compounds dubbed ...
Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback